M. Markman

发表

The use of chemotherapy as palliative treatment for patients with advanced ovarian cancer.

M. Markman, 1995, Seminars in oncology.

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report.

K. Hatch, W. Creasman, W. Barnes, 1996, Gynecologic oncology.

Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.

S. Waggoner, R. Alvarez, K. Hall, 2000, Gynecologic oncology.

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

Robert J. Mayer, Walter J. Curran, J. Crowley, 2001, Journal of the National Cancer Institute.

Limits to the "benefits" from our oncologic interventions: a case report.

M. Markman, 2000, Gynecologic oncology.

Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer.

A. Kennedy, J. Belinson, K. Webster, 1999, Gynecologic oncology.

Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.

H. Ball, S. Lentz, J. Blessing, 1998, Gynecologic oncology.

Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.

M. Markman, 1994, Seminars in oncology.

Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study.

R. Burger, D. Spriggs, H. Gallion, 2001, Gynecologic oncology.

Intraperitoneal chemotherapy.

M. Markman, 1999, Critical reviews in oncology/hematology.

Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.

P. Rose, I. Horowitz, W. Mcguire, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors.

A. Kennedy, J. Belinson, K. Webster, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer.

S. Lichtman, H. Homesley, G. Omura, 1998, Gynecologic oncology.

Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity.

M. Markman, Maurie Markman, 1986, Cancer treatment reviews.

Follow-up of the asymptomatic patient with ovarian cancer.

M. Markman, 1994, Gynecologic oncology.

Salvage therapy in ovarian cancer: is there a role for intraperitoneal drug delivery?

M. Markman, 1993, Gynecologic oncology.

Surgery for support and palliation in patients with malignant disease.

M. Markman, 1995, Seminars in oncology.

Intraperitoneal therapy of ovarian cancer.

M. Markman, 1998, Seminars in oncology.

Is there a role for intraperitoneal therapy in the management of gastrointestinal malignancies?

M. Markman, 1995, Cancer investigation.

Second-line chemotherapy for refractory cancer: intraperitoneal chemotherapy.

M. Markman, 1994, Seminars in surgical oncology.

Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity.

M. Markman, 1993, Critical reviews in oncology/hematology.

Clinical features of hypersensitivity reactions to carboplatin.

P. Elson, A. Kennedy, J. Belinson, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.

J. Blessing, A. Manetta, F. Major, 1993, Gynecologic oncology.

Intraperitoneal paclitaxel in the management of ovarian cancer.

M. Markman, 1995, Seminars in oncology.

Weekly paclitaxel in the management of ovarian cancer.

M. Markman, 2000, Seminars in oncology.

Prolonged symptom-free survival in a patient with persistent primary peritoneal carcinoma and a rising CA-125: a note of caution.

M. Markman, 2001, Gynecologic oncology.

When regulatory requirements conflict with ethical study design: the case of oral ondansetron.

M. Markman, M. Markman, 1994, Cancer investigation.

Should cost be considered in the overall evaluation of phase II clinical trials of new antineoplastic therapies?

M. Markman, 1996, Cancer investigation.

Profile of ovarian cancer patients seeking information from a web-based decision support program.

M. Markman, J. Petersen, A. Belland, 2006, Journal of women's health.

Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.

M. Markman, B. Kulp, G. Peterson, 2002, Gynecologic oncology.

Amifostine in reducing cisplatin toxicity.

M. Markman, 1998, Seminars in oncology.

Intraperitoneal chemotherapy in the management of colon cancer.

M. Markman, 1999, Seminars in oncology.

Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies.

F. Muggia, M. Israel, J. Soper, 1996, Gynecologic Oncology.

Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer?

P. Francis, E. Rowinsky, M. Markman, 1995, Seminars in oncology.

Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity.

M. Markman, B. Kulp, G. Peterson, 2003, Gynecologic oncology.

Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer.

M. Markman, 1997, Seminars in Oncology.

Parkinsonism following i.v. administration of high-dose metoclopramide used as an antiemetic agent during cancer chemotherapy.

M. Markman, D. Newman, R. S. Hawkins, 1985, Cancer treatment reports.

Topotecan: an important new drug in the management of ovarian cancer.

M. Markman, 1997, Seminars in oncology.